Seelos therapeutics announces the participation of acadia healthcare in the registration directed study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major depressive disorder

- acadia healthcare is the largest stand-alone behavioral health company in the united states operating a network of nearly 240 behavioral health facilities in 39 states and puerto rico new york , sept. 13, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the participation of acadia healthcare company, inc. (nasdaq: achc) in the registration directed proof of concept study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior (asib) in patients with major depressive disorder (mdd).
ACHC Ratings Summary
ACHC Quant Ranking